Quintiles Transnational Holdings Inc (Q) was Resumed by Barclays to “Overweight” and the brokerage firm has set the Price Target at $90. Barclays advised their investors in a research report released on Nov 30, 2016.
Many Wall Street Analysts have commented on Quintiles Transnational Holdings Inc. Quintiles Transnational Holdings Inc was Downgraded by Piper Jaffray to ” Neutral” on Oct 27, 2016. Quintiles Transnational Holdings Inc was Downgraded by Jefferies to ” Hold” on Oct 19, 2016. Stifel Initiated Quintiles Transnational Holdings Inc on Oct 14, 2016 to “Hold”, Price Target of the shares are set at $84.
On the company’s financial health, Quintiles Transnational Holdings Inc reported $1.00 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Nov 2, 2016. Analyst had a consensus of $0.99. The company had revenue of $1136.40 million for the quarter, compared to analysts expectations of $1157.91 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.
Quintiles Transnational Holdings Inc opened for trading at $80.02 and hit $81.15 on the upside on Tuesday, eventually ending the session at $80.93, with a gain of 1.39% or 1.11 points. The heightened volatility saw the trading volume jump to 17,37,841 shares. Company has a market cap of $19,923 M.
In a different news, on Nov 22, 2016, Jack M Greenberg (director) sold 2,000 shares at $79.77 per share price. According to the SEC, on Jun 10, 2016, Kevin K Gordon (EVP and COO) sold 24,000 shares at $66.41 per share price. On May 16, 2016, Annie H. Lo (director) purchased 502 shares at $64.80 per share price, according to the Form-4 filing with the securities and exchange commission.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services including commercial services such as contract pharmaceutical sales forces and healthcare business services such as phase research market access and consulting and health information analytics and technology consulting.